NCT02430103View on ClinicalTrials.gov

Study of Preservation of Ovarian Reserve During Chemotherapy for Young Breast Cancer Patients

Active, not recruitingOBSERVATIONAL
Enrollment

349

Participants

Timeline

Start Date

December 25, 2015

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2024

Conditions
Breast Cancer
Interventions
DRUG

Goserelin 3.6 MG

In goserelin group, goserelin 3.6mg will be administered every 28 days by subcutaneous injection starting at least 7-14 days before the first cycle of chemotherapy and continued throughout chemotherapy duration.

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER

NCT02430103 - Study of Preservation of Ovarian Reserve During Chemotherapy for Young Breast Cancer Patients | Biotech Hunter | Biotech Hunter